quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:35:00·2d
PRRelease
Revolution Medicines Inc. logo

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

RVMD· Revolution Medicines Inc.
Health Care
Original source

Companies

  • RVMD
    Revolution Medicines Inc.
    Health Care

Recent analyst ratings

  • Mar 16UpdateJefferies-
  • Feb 27UpdateUBS$145.00
  • Nov 18UpdateWolfe Research$75.00
  • Nov 3UpdateRBC Capital Mkts$77.00
  • Oct 21UpdateMizuho$90.00
  • Oct 16UpdateStifel$85.00

Related

  • PR2d
    Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
  • PR2d
    Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
  • INSIDER6d
    SEC Form 4 filed by Goldsmith Mark A
  • SEC6d
    Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
  • PR6d
    Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
  • SEC7d
    SEC Form 8-K filed by Revolution Medicines Inc.
  • SEC8d
    SEC Form 424B5 filed by Revolution Medicines Inc.
  • SEC8d
    SEC Form 424B5 filed by Revolution Medicines Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022